JPS615016A - 活性酸素除去剤 - Google Patents
活性酸素除去剤Info
- Publication number
- JPS615016A JPS615016A JP12340684A JP12340684A JPS615016A JP S615016 A JPS615016 A JP S615016A JP 12340684 A JP12340684 A JP 12340684A JP 12340684 A JP12340684 A JP 12340684A JP S615016 A JPS615016 A JP S615016A
- Authority
- JP
- Japan
- Prior art keywords
- active oxygen
- fisetin
- remover
- active
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract description 14
- 229910052760 oxygen Inorganic materials 0.000 title abstract description 14
- 239000001301 oxygen Substances 0.000 title abstract description 14
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000011990 fisetin Nutrition 0.000 claims abstract description 12
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 abstract description 3
- 238000010253 intravenous injection Methods 0.000 abstract description 3
- 208000019423 liver disease Diseases 0.000 abstract description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 229930003935 flavonoid Natural products 0.000 abstract description 2
- 150000002215 flavonoids Chemical class 0.000 abstract description 2
- 235000017173 flavonoids Nutrition 0.000 abstract description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract description 2
- 150000002978 peroxides Chemical class 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 1
- 230000002718 inhibitory effect on inflammation Effects 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical class N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12340684A JPS615016A (ja) | 1984-06-15 | 1984-06-15 | 活性酸素除去剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12340684A JPS615016A (ja) | 1984-06-15 | 1984-06-15 | 活性酸素除去剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS615016A true JPS615016A (ja) | 1986-01-10 |
JPH0522687B2 JPH0522687B2 (enrdf_load_stackoverflow) | 1993-03-30 |
Family
ID=14859764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP12340684A Granted JPS615016A (ja) | 1984-06-15 | 1984-06-15 | 活性酸素除去剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS615016A (enrdf_load_stackoverflow) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0725761A (ja) * | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
JP2007514705A (ja) * | 2003-12-18 | 2007-06-07 | アノキシマー ゲーエムベーハー | 慢性および/または炎症性疾患治療のためのアロイジア/バーベナ/リッピア・トリフィラ/シトリオドラの抽出物の使用 |
JP2017105777A (ja) * | 2015-12-08 | 2017-06-15 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 皮膚改善用組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0712529U (ja) * | 1993-08-09 | 1995-03-03 | 鹿島建設株式会社 | 地下連続壁掘削機の掘削アタッチメント洗浄装置 |
-
1984
- 1984-06-15 JP JP12340684A patent/JPS615016A/ja active Granted
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0725761A (ja) * | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
JP2007514705A (ja) * | 2003-12-18 | 2007-06-07 | アノキシマー ゲーエムベーハー | 慢性および/または炎症性疾患治療のためのアロイジア/バーベナ/リッピア・トリフィラ/シトリオドラの抽出物の使用 |
JP2017105777A (ja) * | 2015-12-08 | 2017-06-15 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 皮膚改善用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPH0522687B2 (enrdf_load_stackoverflow) | 1993-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100638684B1 (ko) | 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도 | |
KR950002150B1 (ko) | 레보도파 메틸에스테르를 함유하는 제약 조성물 | |
Mahmoud et al. | Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma | |
ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
WO2002062332A1 (de) | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose | |
JP2001520656A (ja) | 抗腫瘍剤としてのホルボールエステル類 | |
WO2003086074A1 (en) | Method for treating hepatic encephalopathies | |
TW201902474A (zh) | 用於治療中風及減少神經損傷的化合物及其用途 | |
Barach et al. | Inhalation of Nebulized Promin in Experimental Tuberculosis: Sodium P, P'-Diaminodiphenylsulfone-N, N'-Didextrose Sulfonate | |
KR20010101492A (ko) | 멜라가트란의 신규 용도 | |
US6498173B1 (en) | Synergistic combination comprising roflumilast and a pde-3 inhibitor | |
JPS615016A (ja) | 活性酸素除去剤 | |
TWI472519B (zh) | 含正-亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能 | |
JPH08512311A (ja) | 慢性疲労症候群治療用ヒ素医薬 | |
SE534514C2 (sv) | Komposition för behandling av allergiska sjukdomar | |
JPH03170475A (ja) | 抑うつ症治療剤 | |
US5153221A (en) | Method for the treatment of acquired immune deficiency syndrome | |
Hollister et al. | Thioridazine (Mellaril®) in Psychiatric Patients | |
JP2752250B2 (ja) | 鎮痛及び抗炎症作用を有する基礎治療剤 | |
JP2003171266A (ja) | キシリトールを含有する解熱性調剤 | |
CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
JP3064360B2 (ja) | 痴呆治療剤 | |
JPH04210631A (ja) | 消化管壁保護剤 | |
KR100305044B1 (ko) | 콜로이드성이산화규소를함유하는겸상적혈구빈혈증,말라리아및외인적으로유발된백혈구감소증치료를위한치료제 | |
JPS6345371B2 (enrdf_load_stackoverflow) |